Annual Report

Overview

The report highlights Lytix Biopharma's 2024 progress toward commercialization, including a 97% calculated objective response rate for LTX-315 in Verrica's Phase II basal cell carcinoma study. It describes continued advancement of the NeoLIPA and ATLAS-IT-05 programs and preparation of LTX-401 for clinical trials. Financially, revenue reached NOK 11,134 thousand and the company raised NOK 161 million through two funding rounds. The report also introduces an ESG materiality assessment covering environmental, social, and governance topics.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2024
Period: Ends 31 December 2024
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services